Marked increase in gastric acid secretory capacity after omeprazole treatment.

H L Waldum, J S Arnestad, E Brenna, I Eide, U Syversen, A K Sandvik

Department of Medicine, University Hospital, Trondheim, Norway.

BACKGROUND: In contrast with the histamine2 (H2) blockers, proton pump inhibitors have not been shown to give rebound hypersecretion of acid. Taking into consideration the hyperplasia of the enterochromaffin-like (ECL) cell provoked by hypergastrinaemia secondary to profound acid inhibition and the central role of histamine from ECL cells in the regulation of acid secretion, the lack of any rebound acid hypersecretion after treatment with proton pump inhibitors has been questioned. AIMS: To reassess the effect of treatment with omeprazole on post-treatment acid secretion. METHODS AND PATIENTS: Basal and pentagastrin stimulated acid secretion were determined in nine patients with reflux oesophagitis before and 14 days after termination of a 90 day treatment period with the proton pump inhibitor omeprazole (40 mg daily). Basal gastrin release were determined before and during omeprazole treatment. Furthermore, biopsy samples from the oxyntic mucosa were taken before and at the end of the treatment period for chemical (histamine and chromogranin A (CgA)) evaluation of the ECL cell mass. RESULTS: A substantial increase in meal stimulated gastrin release during omeprazole treatment resulted in an increased ECL cell mass. Furthermore, CgA in serum increased during omeprazole treatment suggesting that serum CgA may be used as a test to evaluate ECL cell hyperplasia. A significant increase in basal and a marked (50%) and significant increase in pentagastrin stimulated acid secretion were found after treatment with omeprazole. CONCLUSIONS: Increased acid secretion after a conventional treatment period with a proton pump inhibitor is probably due to ECL cell hyperplasia and may have negative consequences for acid related diseases.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Jansson, A. M., Rosjo, H., Omland, T., Karlsson, T., Hartford, M., Flyvbjerg, A., Caidahl, K. (2009). Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30: 25-32 [Abstract] [Full Text]  
• Ito, K., Kinoshita, K., Tomizawa, A., Morikawa-Inomata, Y., Inaba, F., Fujita, Y., Tabata, K., Shibakawa, N. (2008). The Effect of Subchronic Administration of 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a Novel Acid Pump Antagonist, on Gastric Acid Secretion and Gastrin Levels in Rats. J. Pharmacol. Exp. Ther. 326: 163-170 [Abstract] [Full Text]  
• Welage, L. S. (2005). Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm 62: S4-S10 [Abstract] [Full Text]  
• Cui, G., Qvigstad, G., Falkmer, S., Sandvik, A. K., Kawase, S., Waldum, H. L. (2000). Spontaneous ECLomas in cotton rats (Sigmodon hispidus): tumours occurring in hypoacidic/hypergastrinaemic animals with normal parietal cells. Carcinogenesis 21: 23-27 [Abstract] [Full Text]